News
OncoBeta® receives Corporate Excellence Award 2019
OncoBeta recognized as the Most Compassionate Skin Cancer Therapy Provider in 2019.
OncoBeta®, a Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanocytic Skin Cancers (NMSCs), has recently been presented with the CV Magazine’s Corporate Excellence Award for the Most Compassionate Skin Cancer Therapy Provider in 2019.
August 2019 Garching near Munich, Germany. -OncoBeta®, a Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanocytic Skin Cancers (NMSCs), has recently been presented with the CV Magazine’s Corporate Excellence Award for the Most Compassionate Skin Cancer Therapy Provider in 2019.
CV Magazine’s annual Corporate Excellence Awards are handpicked by their dedicated research team based purely on the comprehensive analysis of both qualitative and quantitative research during the past 12 months. The awards are designed to celebrate excellence in a number of core industries across the business landscape, highlighting those who have truly gone above and beyond to succeed in their endeavors, continually innovating, growing and improving.
Corporate Vision is created by a highly experienced and passionate team of business experts, advisors and insiders dedicated to shine a spot on the brightest, best performing and most deserving companies around the world by carefully analyzing what each industry has to offer. Their business experts recognize the very best and promote thesuccess of companies committed to innovation that had the best performance over the past year.
OncoBeta GmbH has been a gamechanger in the way non-melanoma skin cancer (NMSC) is treated. By always having the patient´s perspective in focus, OncoBeta is today helping redefine patient experience. “With our therapeutic for NMSC- the Rhenium-SCT® – OncoBeta offers a personalized, non-invasive and painless alternative for patients suffering from NMSC” -states Shannon D. Brown III, CEO and Managing Director of OncoBeta GmbH – The global incidence of NMSC has been drastically increasing over the past few decades. The standard care options for NMSC are either painful, non-aesthetically desired or invasive. “OncoBeta is part of the story trying to rectify this” -continues Shannon. With the Rhenium-SCT, OncoBeta is not only improving patient outcomes but is also ensuring scalability and patients access to this therapeutic solution.
For more information about the CV Magazine: https://www.cv-magazine.com/2019-aiming-to-improve-overall-patient-outcomes-and-experiences
